Daniel Kelly MD

Daniel Kelly, MD

Intensivist, Division of Medicine Critical Care

Instructor in Pediatrics, Harvard Medical School

    Contact: 617-355-7015
  • Fax: 888-883-9238

Medical Services

Specialties

  • Transfusion Medicine
  • Critical Care

Departments

Programs

  • Medicine Intensive Care Unit
  • Intermediate Care Program
To schedule an appointment: Call 617-355-7015

Experience and Education

Education

Medical School

Warren Alpert Medical School of Brown University, 2007

Providence, RI

Residency, Pediatrics

New York Presbyterian Hospital/ Weill Cornell Medical Center , 2007-2011

New York, NY

Fellowship, Pediatric Critical Care

Boston Children's Hospital, 2011-2014

Boston, MA

Fellowship, Transfusion Medicine

Brigham and Women’s Hospital/ Boston Children’s Hospital, 2014-2015

Boston, MA

Certifications

  • Pediatric Critical Care

  • Pediatrics

  • Transfusion Medicine

Publications

Publications powered by Harvard Catalyst Profiles
  1. Kelly DP, Bairdain S, Zurakowski D, Dodson B, Harney KM, Jennings RW, Trenor CC. Quality improvement program reduces venous thromboembolism in infants and children with long-gap esophageal atresia (LGEA). Pediatr Surg Int. 2016 Jul; 32(7):691-6.
  2. Aubert G, Martin OJ, Horton JL, Lai L, Vega RB, Leone TC, Koves T, Gardell SJ, Krüger M, Hoppel CL, Lewandowski ED, Crawford PA, Muoio DM, Kelly DP. The Failing Heart Relies on Ketone Bodies as a Fuel. Circulation. 2016 Feb 23; 133(8):698-705.
  3. Bairdain S, Kelly DP, Tan C, Dodson B, Zurakowski D, Zurakowksi D, Jennings RW, Trenor CC. High incidence of catheter-associated venous thromboembolic events in patients with long gap esophageal atresia treated with the Foker process. J Pediatr Surg. 2014 Feb; 49(2):370-3.
  4. Kelly D, C Zhang Q, M Soucie J, Manco-Johnson M, Dimichele D. Prevalence of clinical hip abnormalities in haemophilia A and B: an analysis of the UDC database. Haemophilia. 2013 May; 19(3):426-31.
  5. Silver G, Traube C, Kearney J, Kelly D, Yoon MJ, Nash Moyal W, Gangopadhyay M, Shao H, Ward MJ. Detecting pediatric delirium: development of a rapid observational assessment tool. Intensive Care Med. 2012 Jun; 38(6):1025-31.
  6. Kelly DP. Novel communication between myocyte lipid storage and fat burning unveiled. Circ Res. 2012 Mar 2; 110(5):655-7.
  7. Gan Z, Burkart-Hartman EM, Han DH, Finck B, Leone TC, Smith EY, Ayala JE, Holloszy J, Kelly DP. The nuclear receptor PPARß/d programs muscle glucose metabolism in cooperation with AMPK and MEF2. Genes Dev. 2011 Dec 15; 25(24):2619-30.
  8. Kelly DP. Cell biology: Ageing theories unified. Nature. 2011 Feb 17; 470(7334):342-3.
  9. Cresci S, Huss JM, Beitelshees AL, Jones PG, Minton MR, Dorn GW, Kelly DP, Spertus JA, McLeod HL. A PPARa promoter variant impairs ERR-dependent transactivation and decreases mortality after acute coronary ischemia in patients with diabetes. PLoS One. 2010 Sep 03; 5(9):e12584.
  10. Gardell SJ, Roth GP, Kelly DP. Cardiovascular drug discovery in the academic setting: building infrastructure, harnessing strengths, and seeking synergies. J Cardiovasc Transl Res. 2010 Oct; 3(5):431-7.
  11. Show all
  12. Kelly DP. Introduction to the nuclear receptor review series. Circ Res. 2010 May 28; 106(10):1557-8.
  13. Robinson EK, Kelly DP, Mercer DW, Kozar RA. Differential effects of luminal arginine and glutamine on metalloproteinase production in the postischemic gut. JPEN J Parenter Enteral Nutr. 2008 Jul-Aug; 32(4):433-8.
  14. Lopaschuk GD, Kelly DP. Signalling in cardiac metabolism. Cardiovasc Res. 2008 Jul 15; 79(2):205-7.
  15. Madrazo JA, Kelly DP. The PPAR trio: regulators of myocardial energy metabolism in health and disease. J Mol Cell Cardiol. 2008 Jun; 44(6):968-75.
  16. Burkart EM, Sambandam N, Han X, Gross RW, Courtois M, Gierasch CM, Shoghi K, Welch MJ, Kelly DP. Nuclear receptors PPARbeta/delta and PPARalpha direct distinct metabolic regulatory programs in the mouse heart. J Clin Invest. 2007 Dec; 117(12):3930-9.
  17. Dufour CR, Wilson BJ, Huss JM, Kelly DP, Alaynick WA, Downes M, Evans RM, Blanchette M, Giguère V. Genome-wide orchestration of cardiac functions by the orphan nuclear receptors ERRalpha and gamma. Cell Metab. 2007 May; 5(5):345-56.
  18. Luptak I, Balschi JA, Xing Y, Leone TC, Kelly DP, Tian R. Decreased contractile and metabolic reserve in peroxisome proliferator-activated receptor-alpha-null hearts can be rescued by increasing glucose transport and utilization. Circulation. 2005 Oct 11; 112(15):2339-46.
  19. Sambandam N, Morabito D, Wagg C, Finck BN, Kelly DP, Lopaschuk GD. Chronic activation of PPARalpha is detrimental to cardiac recovery after ischemia. Am J Physiol Heart Circ Physiol. 2006 Jan; 290(1):H87-95.
  20. You M, Considine RV, Leone TC, Kelly DP, Crabb DW. Role of adiponectin in the protective action of dietary saturated fat against alcoholic fatty liver in mice. Hepatology. 2005 Sep; 42(3):568-77.
  21. Park SY, Cho YR, Finck BN, Kim HJ, Higashimori T, Hong EG, Lee MK, Danton C, Deshmukh S, Cline GW, Wu JJ, Bennett AM, Rothermel B, Kalinowski A, Russell KS, Kim YB, Kelly DP, Kim JK. Cardiac-specific overexpression of peroxisome proliferator-activated receptor-alpha causes insulin resistance in heart and liver. Diabetes. 2005 Sep; 54(9):2514-24.
  22. Finck BN, Bernal-Mizrachi C, Han DH, Coleman T, Sambandam N, LaRiviere LL, Holloszy JO, Semenkovich CF, Kelly DP. A potential link between muscle peroxisome proliferator- activated receptor-alpha signaling and obesity-related diabetes. Cell Metab. 2005 Feb; 1(2):133-44.
  23. Harris IS, Treskov I, Rowley MW, Heximer S, Kaltenbronn K, Finck BN, Gross RW, Kelly DP, Blumer KJ, Muslin AJ. G-protein signaling participates in the development of diabetic cardiomyopathy. Diabetes. 2004 Dec; 53(12):3082-90.
  24. Kelly DP, Scarpulla RC. Transcriptional regulatory circuits controlling mitochondrial biogenesis and function. Genes Dev. 2004 Feb 15; 18(4):357-68.
  25. Faury G, Pezet M, Knutsen RH, Boyle WA, Heximer SP, McLean SE, Minkes RK, Blumer KJ, Kovacs A, Kelly DP, Li DY, Starcher B, Mecham RP. Developmental adaptation of the mouse cardiovascular system to elastin haploinsufficiency. J Clin Invest. 2003 Nov; 112(9):1419-28.
  26. Bernal-Mizrachi C, Weng S, Feng C, Finck BN, Knutsen RH, Leone TC, Coleman T, Mecham RP, Kelly DP, Semenkovich CF. Dexamethasone induction of hypertension and diabetes is PPAR-alpha dependent in LDL receptor-null mice. Nat Med. 2003 Aug; 9(8):1069-75.
  27. Kelly DP. PPARs of the heart: three is a crowd. Circ Res. 2003 Mar 21; 92(5):482-4.
  28. Finck BN, Han X, Courtois M, Aimond F, Nerbonne JM, Kovacs A, Gross RW, Kelly DP. A critical role for PPARalpha-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content. Proc Natl Acad Sci U S A. 2003 Feb 4; 100(3):1226-31.
  29. Clabby ML, Robison TA, Quigley HF, Wilson DB, Kelly DP. Retinoid X receptor alpha represses GATA-4-mediated transcription via a retinoid-dependent interaction with the cardiac-enriched repressor FOG-2. J Biol Chem. 2003 Feb 21; 278(8):5760-7.
  30. Baar K, Wende AR, Jones TE, Marison M, Nolte LA, Chen M, Kelly DP, Holloszy JO. Adaptations of skeletal muscle to exercise: rapid increase in the transcriptional coactivator PGC-1. FASEB J. 2002 Dec; 16(14):1879-86.
  31. Finck BN, Kelly DP. Peroxisome proliferator-activated receptor alpha (PPARalpha) signaling in the gene regulatory control of energy metabolism in the normal and diseased heart. J Mol Cell Cardiol. 2002 Oct; 34(10):1249-57.
  32. Huss JM, Kopp RP, Kelly DP. Peroxisome proliferator-activated receptor coactivator-1alpha (PGC-1alpha) coactivates the cardiac-enriched nuclear receptors estrogen-related receptor-alpha and -gamma. Identification of novel leucine-rich interaction motif within PGC-1alpha. J Biol Chem. 2002 Oct 25; 277(43):40265-74.
  33. Lehman JJ, Kelly DP. Transcriptional activation of energy metabolic switches in the developing and hypertrophied heart. Clin Exp Pharmacol Physiol. 2002 Apr; 29(4):339-45.
  34. Lehman JJ, Kelly DP. Gene regulatory mechanisms governing energy metabolism during cardiac hypertrophic growth. Heart Fail Rev. 2002 Apr; 7(2):175-85.
  35. Kelly DP. Peroxisome proliferator-activated receptor alpha as a genetic determinant of cardiac hypertrophic growth: culprit or innocent bystander? Circulation. 2002 Mar 5; 105(9):1025-7.
  36. Finck BN, Lehman JJ, Leone TC, Welch MJ, Bennett MJ, Kovacs A, Han X, Gross RW, Kozak R, Lopaschuk GD, Kelly DP. The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J Clin Invest. 2002 Jan; 109(1):121-30.
  37. Campbell FM, Kozak R, Wagner A, Altarejos JY, Dyck JR, Belke DD, Severson DL, Kelly DP, Lopaschuk GD. A role for peroxisome proliferator-activated receptor alpha (PPARalpha ) in the control of cardiac malonyl-CoA levels: reduced fatty acid oxidation rates and increased glucose oxidation rates in the hearts of mice lacking PPARalpha are associated with higher concentrations of malonyl-CoA and reduced expression of malonyl-CoA decarboxylase. J Biol Chem. 2002 Feb 8; 277(6):4098-103.
  38. Leone TC, Lehman JJ, Finck BN, Schaeffer PJ, Wende AR, Boudina S, Courtois M, Wozniak DF, Sambandam N, Bernal-Mizrachi C, Chen Z, Holloszy JO, Medeiros DM, Schmidt RE, Saffitz JE, Abel ED, Semenkovich CF, Kelly DP. PGC-1alpha deficiency causes multi-system energy metabolic derangements: muscle dysfunction, abnormal weight control and hepatic steatosis. PLoS Biol. 2005 Apr; 3(4):e101.
  39. Finck BN, Gropler MC, Chen Z, Leone TC, Croce MA, Harris TE, Lawrence JC, Kelly DP. Lipin 1 is an inducible amplifier of the hepatic PGC-1alpha/PPARalpha regulatory pathway. Cell Metab. 2006 Sep; 4(3):199-210.
  40. Yang J, Williams RS, Kelly DP. Bcl3 interacts cooperatively with peroxisome proliferator-activated receptor gamma (PPARgamma) coactivator 1alpha to coactivate nuclear receptors estrogen-related receptor alpha and PPARalpha. Mol Cell Biol. 2009 Aug; 29(15):4091-102.
  41. Yang J, Sambandam N, Han X, Gross RW, Courtois M, Kovacs A, Febbraio M, Finck BN, Kelly DP. CD36 deficiency rescues lipotoxic cardiomyopathy. Circ Res. 2007 Apr 27; 100(8):1208-17.
  42. Duncan JG, Bharadwaj KG, Fong JL, Mitra R, Sambandam N, Courtois MR, Lavine KJ, Goldberg IJ, Kelly DP. Rescue of cardiomyopathy in peroxisome proliferator-activated receptor-alpha transgenic mice by deletion of lipoprotein lipase identifies sources of cardiac lipids and peroxisome proliferator-activated receptor-alpha activators. Circulation. 2010 Jan 26; 121(3):426-35.
  43. Beitelshees AL, Finck BN, Leone TC, Cresci S, Wu J, Province MA, Fabbrini E, Kirk E, Zineh I, Klein S, Spertus JA, Kelly DP. Interaction between the UCP2 -866 G&gtA polymorphism, diabetes, and beta-blocker use among patients with acute coronary syndromes. Pharmacogenet Genomics. 2010 Apr; 20(4):231-8.
  44. Lai L, Leone TC, Zechner C, Schaeffer PJ, Kelly SM, Flanagan DP, Medeiros DM, Kovacs A, Kelly DP. Transcriptional coactivators PGC-1alpha and PGC-lbeta control overlapping programs required for perinatal maturation of the heart. Genes Dev. 2008 Jul 15; 22(14):1948-61.
  45. Schaeffer PJ, Desantiago J, Yang J, Flagg TP, Kovacs A, Weinheimer CJ, Courtois M, Leone TC, Nichols CG, Bers DM, Kelly DP. Impaired contractile function and calcium handling in hearts of cardiac-specific calcineurin b1-deficient mice. Am J Physiol Heart Circ Physiol. 2009 Oct; 297(4):H1263-73.
  46. Marionneau C, Aimond F, Brunet S, Niwa N, Finck B, Kelly DP, Nerbonne JM. PPARalpha-mediated remodeling of repolarizing voltage-gated K+ (Kv) channels in a mouse model of metabolic cardiomyopathy. J Mol Cell Cardiol. 2008 Jun; 44(6):1002-15.
  47. Kelly DP. Hypoxic reprogramming. Nat Genet. 2008 Feb; 40(2):132-4.
  48. Schilling J, Lai L, Sambandam N, Dey CE, Leone TC, Kelly DP. Toll-like receptor-mediated inflammatory signaling reprograms cardiac energy metabolism by repressing peroxisome proliferator-activated receptor ? coactivator-1 signaling. Circ Heart Fail. 2011 Jul; 4(4):474-82.
  49. Duncan JG, Fong JL, Medeiros DM, Finck BN, Kelly DP. Insulin-resistant heart exhibits a mitochondrial biogenic response driven by the peroxisome proliferator-activated receptor-alpha/PGC-1alpha gene regulatory pathway. Circulation. 2007 Feb 20; 115(7):909-17.
  50. Banke NH, Wende AR, Leone TC, O'Donnell JM, Abel ED, Kelly DP, Lewandowski ED. Preferential oxidation of triacylglyceride-derived fatty acids in heart is augmented by the nuclear receptor PPARalpha. Circ Res. 2010 Jul 23; 107(2):233-41.
  51. Trausch-Azar J, Leone TC, Kelly DP, Schwartz AL. Ubiquitin proteasome-dependent degradation of the transcriptional coactivator PGC-1{alpha} via the N-terminal pathway. J Biol Chem. 2010 Dec 17; 285(51):40192-200.
  52. Schaeffer PJ, Wende AR, Magee CJ, Neilson JR, Leone TC, Chen F, Kelly DP. Calcineurin and calcium/calmodulin-dependent protein kinase activate distinct metabolic gene regulatory programs in cardiac muscle. J Biol Chem. 2004 Sep 17; 279(38):39593-603.
  53. Chambers KT, Leone TC, Sambandam N, Kovacs A, Wagg CS, Lopaschuk GD, Finck BN, Kelly DP. Chronic inhibition of pyruvate dehydrogenase in heart triggers an adaptive metabolic response. J Biol Chem. 2011 Apr 01; 286(13):11155-62.
  54. Russell LK, Mansfield CM, Lehman JJ, Kovacs A, Courtois M, Saffitz JE, Medeiros DM, Valencik ML, McDonald JA, Kelly DP. Cardiac-specific induction of the transcriptional coactivator peroxisome proliferator-activated receptor gamma coactivator-1alpha promotes mitochondrial biogenesis and reversible cardiomyopathy in a developmental stage-dependent manner. Circ Res. 2004 Mar 5; 94(4):525-33.
  55. Lehman JJ, Boudina S, Banke NH, Sambandam N, Han X, Young DM, Leone TC, Gross RW, Lewandowski ED, Abel ED, Kelly DP. The transcriptional coactivator PGC-1alpha is essential for maximal and efficient cardiac mitochondrial fatty acid oxidation and lipid homeostasis. Am J Physiol Heart Circ Physiol. 2008 Jul; 295(1):H185-96.
  56. Finck BN, Kelly DP. Peroxisome proliferator-activated receptor gamma coactivator-1 (PGC-1) regulatory cascade in cardiac physiology and disease. Circulation. 2007 May 15; 115(19):2540-8.
  57. Zechner C, Lai L, Zechner JF, Geng T, Yan Z, Rumsey JW, Collia D, Chen Z, Wozniak DF, Leone TC, Kelly DP. Total skeletal muscle PGC-1 deficiency uncouples mitochondrial derangements from fiber type determination and insulin sensitivity. Cell Metab. 2010 Dec 1; 12(6):633-42.
  58. Huss JM, Torra IP, Staels B, Giguère V, Kelly DP. Estrogen-related receptor alpha directs peroxisome proliferator-activated receptor alpha signaling in the transcriptional control of energy metabolism in cardiac and skeletal muscle. Mol Cell Biol. 2004 Oct; 24(20):9079-91.
  59. Tordjman K, Standley KN, Bernal-Mizrachi C, Leone TC, Coleman T, Kelly DP, Semenkovich CF. PPARalpha suppresses insulin secretion and induces UCP2 in insulinoma cells. J Lipid Res. 2002 Jun; 43(6):936-43.
  60. Wende AR, Huss JM, Schaeffer PJ, Giguère V, Kelly DP. PGC-1alpha coactivates PDK4 gene expression via the orphan nuclear receptor ERRalpha: a mechanism for transcriptional control of muscle glucose metabolism. Mol Cell Biol. 2005 Dec; 25(24):10684-94.
  61. Schaeffer PJ, Villarin JJ, Pierotti DJ, Kelly DP, Lindstedt SL. Cost of transport is increased after cold exposure in Monodelphis domestica: training for inefficiency. J Exp Biol. 2005 Aug; 208(Pt 16):3159-67.
  62. Huss JM, Kelly DP. Mitochondrial energy metabolism in heart failure: a question of balance. J Clin Invest. 2005 Mar; 115(3):547-55.
  63. Huss JM, Kelly DP. Nuclear receptor signaling and cardiac energetics. Circ Res. 2004 Sep 17; 95(6):568-78.
  64. Dávila-Román VG, Vedala G, Herrero P, de las Fuentes L, Rogers JG, Kelly DP, Gropler RJ. Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 2002 Jul 17; 40(2):271-7.
  65. de las Fuentes L, Herrero P, Peterson LR, Kelly DP, Gropler RJ, Dávila-Román VG. Myocardial fatty acid metabolism: independent predictor of left ventricular mass in hypertensive heart disease. Hypertension. 2003 Jan; 41(1):83-7.
  66. Erol E, Kumar LS, Cline GW, Shulman GI, Kelly DP, Binas B. Liver fatty acid binding protein is required for high rates of hepatic fatty acid oxidation but not for the action of PPARalpha in fasting mice. FASEB J. 2004 Feb; 18(2):347-9.
  67. Schilling J, Kelly DP. The PGC-1 cascade as a therapeutic target for heart failure. J Mol Cell Cardiol. 2011 Oct; 51(4):578-83.
  68. Wende AR, Schaeffer PJ, Parker GJ, Zechner C, Han DH, Chen MM, Hancock CR, Lehman JJ, Huss JM, McClain DA, Holloszy JO, Kelly DP. A role for the transcriptional coactivator PGC-1alpha in muscle refueling. J Biol Chem. 2007 Dec 14; 282(50):36642-51.
  69. Huss JM, Imahashi K, Dufour CR, Weinheimer CJ, Courtois M, Kovacs A, Giguère V, Murphy E, Kelly DP. The nuclear receptor ERRalpha is required for the bioenergetic and functional adaptation to cardiac pressure overload. Cell Metab. 2007 Jul; 6(1):25-37.
  70. Cresci S, Jones PG, Sucharov CC, Marsh S, Lanfear DE, Garsa A, Courtois M, Weinheimer CJ, Wu J, Province MA, Kelly DP, McLeod HL, Spertus JA. Interaction between PPARA genotype and beta-blocker treatment influences clinical outcomes following acute coronary syndromes. Pharmacogenomics. 2008 Oct; 9(10):1403-17.
  71. Finck BN, Kelly DP. PGC-1 coactivators: inducible regulators of energy metabolism in health and disease. J Clin Invest. 2006 Mar; 116(3):615-22.
  72. Mitra R, Nogee DP, Zechner JF, Yea K, Gierasch CM, Kovacs A, Medeiros DM, Kelly DP, Duncan JG. The transcriptional coactivators, PGC-1a and ß, cooperate to maintain cardiac mitochondrial function during the early stages of insulin resistance. J Mol Cell Cardiol. 2012 Mar; 52(3):701-10.
  73. Russell LK, Finck BN, Kelly DP. Mouse models of mitochondrial dysfunction and heart failure. J Mol Cell Cardiol. 2005 Jan; 38(1):81-91.
  74. Ahn B, Soundarapandian MM, Sessions H, Peddibhotla S, Roth GP, Li JL, Sugarman E, Koo A, Malany S, Wang M, Yea K, Brooks J, Leone TC, Han X, Vega RB, Kelly DP. MondoA coordinately regulates skeletal myocyte lipid homeostasis and insulin signaling. J Clin Invest. 2016 Sep 1; 126(9):3567-79.
  75. Liu J, Liang X, Zhou D, Lai L, Xiao L, Liu L, Fu T, Kong Y, Zhou Q, Vega RB, Zhu MS, Kelly DP, Gao X, Gan Z. Coupling of mitochondrial function and skeletal muscle fiber type by a miR-499/Fnip1/AMPK circuit. EMBO Mol Med. 2016 Oct 04; 8(10):1212-1228.
  76. Muszynski JA, Spinella PC, Cholette JM, Acker JP, Hall MW, Juffermans NP, Kelly DP, Blumberg N, Nicol K, Liedel J, Doctor A, Remy KE, Tucci M, Lacroix J, Norris PJ. Transfusion-related immunomodulation: review of the literature and implications for pediatric critical illness. Transfusion. 2016 Oct 2.
  77. Dorn GW, Vega RB, Kelly DP. Mitochondrial biogenesis and dynamics in the developing and diseased heart. Genes Dev. 2015 Oct 1; 29(19):1981-91.
  78. Liang X, Liu L, Fu T, Zhou Q, Zhou D, Xiao L, Liu J, Kong Y, Xie H, Yi F, Lai L, Vega RB, Kelly DP, Smith SR, Gan Z. Exercise Inducible Lactate Dehydrogenase B Regulates Mitochondrial Function in Skeletal Muscle. J Biol Chem. 2016 Oct 13.
  79. Gong G, Song M, Csordas G, Kelly DP, Matkovich SJ, Dorn GW. Parkin-mediated mitophagy directs perinatal cardiac metabolic maturation in mice. Science. 2015 Dec 4; 350(6265):aad2459.
  80. Theodosakis N, Micevic G, Kelly DP, Bosenberg M. Mitochondrial function in melanoma. Arch Biochem Biophys. 2014 Dec 1; 563:56-9.
  81. Vega RB, Horton JL, Kelly DP. Maintaining ancient organelles: mitochondrial biogenesis and maturation. Circ Res. 2015 May 22; 116(11):1820-34.
  82. Weinheimer CJ, Lai L, Kelly DP, Kovacs A. Novel mouse model of left ventricular pressure overload and infarction causing predictable ventricular remodelling and progression to heart failure. Clin Exp Pharmacol Physiol. 2015 Jan; 42(1):33-40.
  83. Horton JL, Martin OJ, Lai L, Riley NM, Richards AL, Vega RB, Leone TC, Pagliarini DJ, Muoio DM, Bedi KC, Margulies KB, Coon JJ, Kelly DP. Mitochondrial protein hyperacetylation in the failing heart. JCI Insight. 2016 Feb; 2(1).
To schedule an appointment: Call 617-355-7015

Locations

We are grateful to have been ranked #1 on U.S. News & World Report's list of the best children's hospitals in the nation for the third year in a row, an honor we could not have achieved without the patients and families who inspire us to do our very best for them. Thanks to you, Boston Children's is a place where we can write the greatest children's stories ever told.”
- Sandra L. Fenwick, President and CEO

Boston Children's Hospital 300 Longwood Avenue, Boston, MA 02115 617-355-6000 | 800-355-7944

Close